Assessment of serum cytokines predicts clinical and endoscopic outcomes to vedolizumab in ulcerative colitis patients.
cytokines
inflammation
translational research
Journal
British journal of clinical pharmacology
ISSN: 1365-2125
Titre abrégé: Br J Clin Pharmacol
Pays: England
ID NLM: 7503323
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
12
08
2019
revised:
26
11
2019
accepted:
01
12
2019
pubmed:
7
2
2020
medline:
27
7
2021
entrez:
7
2
2020
Statut:
ppublish
Résumé
Vedolizumab (VDZ) prevents migration of activated leucocytes into inflamed mucosa. This study aimed to assess the patterns of serum cytokines in ulcerative colitis (UC) patients at baseline and during VDZ treatment, and to investigate their association with mucosal healing and clinical remission. We enrolled consecutive UC patients eligible for treatment with VDZ. A panel of serum cytokines were measured by fluorescence assay at weeks 0, 6 and 22. Colonoscopy was performed at baseline and week 54, to evaluate mucosal healing. The time trends of serum cytokines were analysed by log-linear mixed effect models, and their prognostic accuracy was evaluated by logistic regression. Out of 27 patients included in the analysis, at week 54 mucosal healing was achieved in 12 (44%) and clinical remission in 17 (63%). Mucosal healing was associated with higher interleukin (IL)-8 values at baseline and with significant decrease in IL-6 and IL-8 levels over the first 6 weeks. A significant reduction of IL-6 and IL-8 levels over the first 6 weeks of treatment was associated also with clinical remission. Logistic models including, among the predictors, IL-6 and IL-8 at baseline and their changes over the first 6 weeks of treatment had 83% sensitivity and 87% specificity to predict mucosal healing, and 82% sensitivity and 90% specificity to predict clinical remission. In UC patients, the serum patterns of IL-6 and IL-8 at baseline and over the first 6 weeks of treatment with VDZ could be useful to predict therapeutic outcome.
Identifiants
pubmed: 32027388
doi: 10.1111/bcp.14235
pmc: PMC7319004
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Cytokines
0
vedolizumab
9RV78Q2002
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1296-1305Informations de copyright
© 2020 The British Pharmacological Society.
Références
Scand J Gastroenterol. 2009;44(6):727-35
pubmed: 19294580
N Engl J Med. 2013 Aug 22;369(8):699-710
pubmed: 23964932
Immunol Res. 2014 May;58(2-3):224-33
pubmed: 24522699
N Engl J Med. 2011 Nov 3;365(18):1713-25
pubmed: 22047562
Lancet. 2012 Nov 3;380(9853):1590-605
pubmed: 22914295
Gut. 2019 Jan;68(1):25-39
pubmed: 29730603
Scand J Gastroenterol. 2018 May;53(5):579-585
pubmed: 29171305
J Pharmacol Exp Ther. 2009 Sep;330(3):864-75
pubmed: 19509315
World J Gastroenterol. 2018 Sep 7;24(33):3681-3694
pubmed: 30197475
United European Gastroenterol J. 2019 Nov;7(9):1189-1197
pubmed: 31700632
J Crohns Colitis. 2013 Jul;7(6):481-9
pubmed: 22974822
Inflamm Bowel Dis. 2019 Jan 10;25(2):410-420
pubmed: 30295781
Minerva Gastroenterol Dietol. 2019 Dec;65(4):298-308
pubmed: 31646851
J Crohns Colitis. 2011 Oct;5(5):477-83
pubmed: 21939925
World J Gastroenterol. 2018 Jun 21;24(23):2457-2467
pubmed: 29930467
Lancet. 2017 Apr 29;389(10080):1756-1770
pubmed: 27914657
Cold Spring Harb Perspect Biol. 2014 Sep 04;6(10):a016295
pubmed: 25190079
Inflamm Bowel Dis. 2019 Mar 14;25(4):803-810
pubmed: 30295811
Int J Mol Sci. 2017 Aug 22;18(8):
pubmed: 28829369
Expert Rev Gastroenterol Hepatol. 2016;10(2):165-75
pubmed: 26588993
Scand J Gastroenterol. 2015;50(9):1118-26
pubmed: 25877762
Clin Gastroenterol Hepatol. 2019 Apr;17(5):838-846.e2
pubmed: 29935327
Aliment Pharmacol Ther. 2016 May;43(10):1090-102
pubmed: 27038247
Inflamm Bowel Dis. 2019 May 4;25(6):1028-1035
pubmed: 30365009
Gastroenterology. 2007 Feb;132(2):763-86
pubmed: 17258735
Br J Clin Pharmacol. 2020 Jul;86(7):1296-1305
pubmed: 32027388
Aliment Pharmacol Ther. 2016 Dec;44(11-12):1199-1212
pubmed: 27714831
Gastroenterology. 1992 Feb;102(2):514-9
pubmed: 1370661
J Crohns Colitis. 2018 Jan 24;12(2):245-257
pubmed: 29077833
J Crohns Colitis. 2016 Apr;10(4):402-9
pubmed: 26681763
Expert Rev Gastroenterol Hepatol. 2011 Dec;5(6):703-16
pubmed: 22017698
J Gastroenterol Hepatol. 2015 Oct;30(10):1467-72
pubmed: 25968585
Dig Liver Dis. 2014 Nov;46(11):974-9
pubmed: 25096964
Scand J Gastroenterol. 2017 Jun - Jul;52(6-7):722-729
pubmed: 28362144
Cell. 2019 Jul 25;178(3):714-730.e22
pubmed: 31348891
BMJ Open Gastroenterol. 2018 May 31;5(1):e000208
pubmed: 29915667
Curr Gastroenterol Rep. 2013 Mar;15(3):315
pubmed: 23354742
Inflamm Bowel Dis. 2015 Dec;21(12):2879-85
pubmed: 26288002
Nat Rev Gastroenterol Hepatol. 2010 Jan;7(1):15-29
pubmed: 19949430
Front Immunol. 2017 Jul 03;8:764
pubmed: 28717358
Dig Dis Sci. 2018 Sep;63(9):2419-2429
pubmed: 29372476
Aliment Pharmacol Ther. 2017 Aug;46(3):310-321
pubmed: 28593685